Compare Sana Biotechnology Inc (SANA) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Snap Inc — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Snap Inc trades at $6.28 (market cap $9.83B). The key difference: Snap Inc is far larger — about 11.7× Sana Biotechnology Inc's market cap, and Snap Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Snap Inc for 68 Days on average.
| SANA | SNAP | |
|---|---|---|
Market Cap | $836.71M | $9.83B |
Volume | 4,507,444 | 28,532,342 |
Sector | Health | Media |
52-Week High | $5.92 | $9.09 |
52-Week Low | $2.68 | $3.93 |
Typical Hold Time | 23 Days | 68 Days |
Enterprise Value | $749.96M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Snap Inc. (SNAP) trades at $6.235, up 7.31% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. Revenue growth is steady, reaching $5.93B in 2025, though the company remains unprofitable with a net income margin of -4.9%. Recent news highlights AI and AR developments, including partnerships with NVIDIA and Salesforce for its SPECS glasses, driving positive sentiment despite regulatory pressures.
The stock presents a speculative opportunity with analyst consensus pointing to a $7.78 price target, but risks include persistent losses, high debt, and intense competition. Upside hinges on monetizing new AI/AR initiatives, while downside protection is limited by weak profitability and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
